ALL-20250 JuvedermIT catalogue

OUR PRODUCTS HYDRATE IT

with Juvéderm® VOLITE1,*

SMOOTH IT

with Juvéderm® VOLBELLA2,*

FILL IT

with Juvéderm® VOLIFT3,*

VOLUMISE IT

with Juvéderm® VOLUMA4,*

SCULPT IT

with Juvéderm® VOLUX5,*

Model treated with JUVÉDERM®. Results may vary. * Products contain lidocaine,1–5 the addition of which does not alter the physical properties of JUVÉDERM® products. 6 In this document, Juvéderm® VOLBELLA with lidocaine, Juvéderm® VOLIFT with lidocaine and Juvéderm® VOLUMA with lidocaine will be referred to as Juvéderm® VOLBELLA, Juvéderm® VOLIFT and Juvéderm® VOLUMA, respectively.

CONTENTS

JUVÉDERM® IT with our range of products 3–4 ® DISCOVER IT – VYCROSS 5–7 ® The VYCROSS collection: designed and tailored for the most treated areas of the face 5 JUVÉDERM® IT with the VYCROSS® collection 6 Juvederm® VOLUX: an evolution within the VYCROSS® collection 7 ® DISCOVER IT – HYLACROSS 9–11 The HYLACROSS® range: proven technology 9 ® ® JUVÉDERM IT with the HYLACROSS range 10–11 ® WHY JUVÉDERM IT? 12–13 ® The new syringe from JUVÉDERM 14 Employ your skill and artistry with comfort and control 14 References 15

2

VAL! AR R I N EW

JUVÉDERM® IT WITH OUR RANGE OF PRODUCTS

We’re the world’s number one brand of hyaluronic acid (HA) facial fillers.7,* Built on a long heritage of quality, science and meaningful innovation, 8 we’ve created a comprehensive collection of HA fillers1–5,9–13 that are designed and tailored for the most treated areas of the face.14,†

1

Our two patented technologies, HYLACROSS® and VYCROSS®,15 mean you can have fillers with a variety of different characteristics to choose and create bespoke treatment plans for patients16 – for natural-looking changes17,18 with lasting results15,19–21 and satisfaction.18,20,21

* B ased on healthcare professional (HCP) tracking market research, from over 1000 HCPs in the largest 13 aesthetic markets worldwide.7 † B ased on market research involving 756 healthcare professionals from 12 internationalmarkets.14 ‡ Rheological properties of gels are characteristics to describe their physical responses to applied forces in vitro and should not be individually translated to clinical performance. 22,23 § Clinical study assessed lower face as chin and jaw area. 21

3

Juvéderm® VOLUX – our most cohesive, 22,‡ elastic, 23,‡ concentrated HA filler5 – is here!

Juvéderm® VOLUX has been designed to restore and create volume in the chin and jaw area. 21,§

When you want to enhance skin quality1,20,24,*

When you want to refine features and reduce fine lines2,18

When you want to fill lines and shape features3

* S kin quality is defined as smoothness (absence of fine lines), hydration and elasticity. 20 Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%). 20 †C linical study assessed lower face as chin and jaw area. 21

When you want to correct mid-face volume4,25,26

When you want to define the lower face5,21,27,†

Models treated with JUVÉDERM®.

Results may vary.

4

DISCOVER IT – VYCROSS® THE VYCROSS® COLLECTION: DESIGNED AND TAILORED FOR THE MOST TREATED AREAS OF THE FACE14,*

24

Up to months For illustrative purposes only.

VYCROSS® is a collection of products that can fill lines, add volume, shape the face and improve your patients’ skin quality, depending on the treatment chosen1–5,†

For illustrative purposes only.

Duration from 9 to 24 months, depending on which filler you choose18,20,21,25,26,28

Thorough tissue integration, 29–32,‡ which may contribute to the natural look and feel assessed as a result of treatment17,18,29,32,33

* Based on market research involving 756 healthcare professionals from 12 international markets.14 † Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity. 20 Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%). 20 ‡ Tissue integration was demonstrated by Juvéderm® VOLBELLA, Juvéderm® VOLIFT, Juvéderm® VOLUMA and Juvéderm® VOLUX at 4 weeks in animal in vivo studies. 29–32

5

JUVÉDERM® IT WITH THE VYCROSS® COLLECTION Juvéderm® VOLITE

Juvéderm® VOLBELLA

12 mg/mL, 0.3% lidocaine1

Juvéderm® VOLIFT

15 mg/mL, 0.3% lidocaine2

Juvéderm® VOLUMA

17.5 mg/mL, 0.3% lidocaine3

20 mg/mL, 0.3% lidocaine 4

For enhancing skin quality 1,20,24,*

For refining features and reducing fine lines2,18

For filling lines and shaping features3

For correcting mid-face volume4,25,26

Face, hands, neck, décolletage

Forehead lines, periorbital lines, glabellar lines, tear troughs, lips and perioral lines

Forehead lines, eyebrows, cheeks, nasolabial folds, lips and perioral lines, marionette lines, chin

Temple, cheeks and cheekbones

Intradermal1

Superficial, mid-dermis, lips mucosa2

Deep dermis, lips mucosa3

Subcutaneous, upper periostea, deep dermis 4

Up to 12 months’ duration18,34

Up to 18 months’ duration28,35,‡

Up to 9 months’ duration of dermal hydration20,†

2 x 1 mL, 4 x 32 G½”1

9

2 x 1 mL, 4 x 30 G½”2

12

2 x 1 mL, 4 x 30 G½”3

18

Up to 24 months’ duration25,26,§

24

2 x 1 mL, 4 x 27 G½”4

* Skin quality is defined as smoothness (absence of fine lines), hydration and elasticity. 20 Investigator-assessed cheek skin texture (primary endpoint) as a measure of skin smoothness improved in patients at Month 1 (96.2%), Month 4 (76.3%), Month 6 (34.9%) and Month 9 (15.8%). 20 † Cheek skin hydration, as measured by the MoistureMeter ® D instrument, significantly improved from baseline at Months 1, 4, 6 and 9. 20 ‡ 18-month duration in nasolabial folds (NLFs) from clinical data.

Within 4 weeks after the Month 9, 12, or 15 visits, patients could request a single, unilateral treatment to correct clinically significant asymmetry (at least 1-point difference in NLF severity between NLFs, based on the Evaluating Investigator assessment). 28 § One of the studies was conducted using Juvéderm® VOLUMA without lidocaine. 25 The addition of lidocaine does not alter the physical properties of JUVÉDERM® products. 6

6

JUVÉDERM® VOLUX: AN EVOLUTION WITHIN THE VYCROSS® COLLECTION Juvéderm® VOLUX has been designed to restore and create volume in the chin and jaw area21,* for 18–24 months.21,36,† Our new addition:

Juvéderm® VOLUX5 25 mg/mL, 0.3% lidocaine

For defining the lower face5,21,27,*

•

Has the highest levels of cohesivity and elasticity within the VYCROSS® collection22,23,‡

Pogonion, mentum, pre-jowl sulci, sublabial (mental) crease

•

Is designed for lower face areas needing increased projection and defining – chin and jaw area21,*

•

Delivered thorough tissue integration (in a rat model),31 which may contribute to the natural look and feel assessed as a result of treatment32

Subcutaneous, supraperiostal5

18–24 months’ duration21,36,†

18–24

2 x 1 mL, 4 x 27 G½”5

* Clinical study assessed lower face as chin and jaw area. 21 † Based on comparative preclinical in vitro testing and results from repeat treatment data, added to Juvéderm® VOLUX clinical study showing duration beyond 18 months after initial treatment or initial + top-up treatment in the chin and jaw, as well as clinical results for predicate device Juvéderm® VOLUMA with lidocaine showing 24 month duration in the mid-face established Juvéderm® VOLUX as having an in situ dura tion of 18–24 months.36 ‡ Rheological properties of gels are characteristics to describe their physical responses to applied forces in vitro and should not be individually translated to clinical performance. 22,23

7

WHY JUVÉDERM® IT?

1

Trust in JUVÉDERM®, the world’s number one brand of HA facial fillers7,*

Allergan is built on a long heritage of quality, science and meaningful innovation8

* Based on healthcare professional (HCP) tracking market research, from over 1000 HCPs in the largest 13 aesthetic markets worldwide.7

8

For illustrative purposes only.

The JUVÉDERM® collection of HA fillers1–5,9–13 is designed and tailored for the most treated areas of the face…14,*

For illustrative purposes only.

... and feature thorough tissue integration, 29–32,† which may contribute to the natural look and feel assessed as a result of treatment17,18,29,32,33 that patients can be satisfied with.18,20, 21, 25,26,28,41

* Based on market research involving 756 healthcare professionals from 12 international markets.14 † Tissue integration was demonstrated by Juvéderm® ULTRA XC, Juvéderm® ULTRA PLUS XC, Juvéderm® VOLBELLA, Juvéderm® VOLIFT, Juvéderm® VOLUMA and Juvéderm® VOLUX at 4 weeks in animal in vivo studies. 29–32

9

THE NEW SYRINGE FROM JUVÉDERM® EMPLOY YOUR SKILL AND ARTISTRY WITH COMFORT AND CONTROL42,* •

Improved ease of aspiration. 42 Aspiration can help minimise the risk of vascular complications43

•

Improved injection comfort 42

•

Minimal muscle fatigue42

•

Lower exertion pressure required for serial punctures42

Soon to be available for all JUVÉDERM® products.

For illustrative purposes only.

* Compared with the older, existing JUVÉDERM® syringe design (standard). 42

10

REFERENCES 1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

11

Juvéderm® VOLITE DFU. 73140JR11. Revision 2017-07-19.

Juvéderm® VOLBELLA with lidocaine DFU. 72525JR12. Revision 2017-07-19.

Juvéderm® VOLIFT with lidocaine DFU. 72383JR14. Revision 2017-07-19.

Juvéderm® VOLUMA with lidocaine DFU. 72475JR13. Revision 2017-07-19.

Juvéderm® VOLUX DFU. 72778JR10. Revision 2018-07-26.

Raspaldo H et al. J Cosmet Dermatol. 2010;9:11–15.

Allergan. Unpublished Data. INT/0771/2016(2). JUVÉDERM®, the world’s leading brand of hyaluronic acid facial fillers. Feb 2019.

Stephens H. 2000. Allergan’s first fifty years. Lyme, Conn: Greenwich Pub. Group Juvéderm® ULTRA 2 DFU. 72345JR15. Revision 2017-07-19.

Juvéderm® ULTRA 3 DFU. 72490JR13. Revision 2017-07-19.

Juvéderm® ULTRA 4 DFU. 72488JR13. Revision 2017-07-19.

Juvéderm® ULTRA XC DFU. 72360EC12. Revision 2016-02-23.

Juvéderm® ULTRA PLUS XC DFU. 72361EC12. Revision 2016-02-23.

Allergan. Unpublished Data. INT/0023/2017(1). The most treated areas of the face.

Feb 2019.

Goodman GJ et al. Plast Reconstr Surg. 2015;136(5 Suppl):139S–48S. Bernardin A et al. Poster Presentation at the Anti-Aging Medicine European Congress (AMEC), Monte Carlo, Monaco; 2013.

Philipp-Dormston WG et al. J Cosmet Dermatol. 2014;13:125–34.

Eccleston D and Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167–72.

Pinsky MA et al. Aesthet Surg J. 2008;28:17–23.

Niforos F et al. Poster Presentation at Beauty Through Science (BTS) Congress, Stockholm, Sweden; 2017.

Allergan. Data on File. INT/0654/2018. Juvéderm® VOLUX final clinical study report & clinical evaluation report – efficacy and duration data. Oct 2018.

Allergan. Unpublished Data. INT/0011/2018a(1). JUVÉDERM® gel cohesivity data.

May 2018.

Allergan. Unpublished Data. INT/0141/2019. JUVÉDERM® (gel elasticity G’) data. Mar 2019.

24. Allergan. Unpublished Data. INT/0078/2017(1). Juvéderm® VOLITE treatment area.

Mar 2019.

25. Callan P et al. Clin Cosmet Investig Dermatol. 2013;6:81–89.

26. Jones D and Murphy DK. Dermatol Surg. 2013;39:1602–12.

27. Ogilvie P et al. Poster Presentation at Aesthetic & Anti-Aging Medicine World Congress (AMWC), Monte Carlo, Monaco; 2018.

28. Allergan. Unpublished Data. INT/0214/2017(2). Juvéderm® VOLIFT XC US clinical study results (V17-001). Apr 2019.

29. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–81.

30. Allergan. Data on File. INT/0650/2017. JUVÉDERM® tissue integration images. Aug 2017.

31. Allergan. Unpublished Data. INT/0314/2018(1). Juvéderm® VOLUX tissue integration.

May 2018.

32. Allergan. Data on File. INT/0663/2018. Juvéderm® VOLUX final clinical evaluation report.

Oct 2018.

33. Baumann LS. Dermatol Surg. 2007;33(Suppl 2):S128–35.

34. Niforos F et al. Dermatol Surg. 2017;43:1271–80.

35. Allergan. Data on File. INT/0607/2017. Juvéderm® VOLIFT NLFSS responder rates (S17L001). Aug 2017.

36. Allergan. Data on File. INT/0074/2019. Juvéderm® VOLUX final clinical evaluation report.

Jan 2019.

37. Wahl G. J Cosmet Dermatol. 2008;7:298–303.

38. Levy PM et al. Dermatol Surg. 2009;35(Suppl 1):332–37.

39. Goodman GJ et al. Clin Cosmet Investig Dermatol. 2011;4:197–205.

40. Allergan. Data on File. INT/0942/2017. JUVÉDERM® ULTRA ranges. Oct 2017.

41. Hoffman K. for the JUVÉDERM® VOLUMA Study Investigators Group.

BMC Dermatol. 2009;9:9.

42. Allergan. Unpublished Data. INT/0079/2017(1). JUVÉDERM® syringe, ergonomic testing results. Apr 2019.

43. Abduljabbar MH et al. J Dermatol Dermatol Surg. 2016;20:100–06.

WHEN YOU WANT TO JUVÉDERM® IT...

Allergan Norden AB, Strandbergsgatan 61, 112 51 Stockholm, Sverige To report Adverse Events please contact: ProductSurveillance_EAME@Allergan.com

www.juvederm.se www.juvederm.no

juvedermSE juvedermNO

juvederm.se juvederm.no

www.juvederm.dk www.juvederm.fi

juvedermDK juvedermFI

juvederm.dk juvederm.fi

ND/0223/2019. Date of preparation: May 2019

This brochure has been created to help with your ordering needs. Whether you’re looking to restock your most popular facial filler treatments or want to JUVÉDERM® IT with the entire range, all of our facial fillers are available to order, including our new Juvéderm® VOLUX product.